Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis
Background Ibrutinib and acalabrutinib are Bruton tyrosine kinase inhibitors used in the treatment of B‐cell lymphoproliferative disorders. Ibrutinib is associated with new‐onset atrial fibrillation. Cases of sinus bradycardia and sinus arrest have also been reported following ibrutinib treatment. C...
Main Authors: | Jari M. Tuomi, Loryn J. Bohne, Tristan W. Dorey, Hailey J. Jansen, Yingjie Liu, Douglas L. Jones, Robert A. Rose |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-11-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.121.022369 |
Similar Items
-
Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
by: Sining Zhu, et al.
Published: (2021-10-01) -
Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
by: Sining Zhu, et al.
Published: (2021-08-01) -
Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
by: Anselm Morell, et al.
Published: (2020-12-01) -
Genetics of sinoatrial node function and heart rate disorders
by: Lieve E. van der Maarel, et al.
Published: (2023-05-01) -
Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
by: Jia Liu, et al.
Published: (2022-09-01)